Handa Pharmaceuticals (6620) Stock Overview
A specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Risk Analysis
No risks detected for 6620 from our risk checks.
6620 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Handa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$82.50 |
| 52 Week High | NT$95.40 |
| 52 Week Low | NT$49.90 |
| Beta | 0.59 |
| 1 Month Change | -1.55% |
| 3 Month Change | 10.15% |
| 1 Year Change | -4.73% |
| 3 Year Change | 37.50% |
| 5 Year Change | 204.99% |
| Change since IPO | -12.23% |
Recent News & Updates
Shareholder Returns
| 6620 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.9% | 1.5% | 0.9% |
| 1Y | -4.7% | -3.4% | 2.8% |
Return vs Industry: 6620 underperformed the TW Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 6620 underperformed the TW Market which returned 2.8% over the past year.
Price Volatility
| 6620 volatility | |
|---|---|
| 6620 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 7.6% |
| 10% least volatile stocks in TW Market | 2.4% |
Stable Share Price: 6620 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6620's weekly volatility has decreased from 9% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Toshiyo Chen | www.handapharma.com.tw |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug.
Handa Pharmaceuticals, Inc. Fundamentals Summary
| 6620 fundamental statistics | |
|---|---|
| Market cap | NT$13.06b |
| Earnings (TTM) | NT$472.74m |
| Revenue (TTM) | NT$830.67m |
Is 6620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6620 income statement (TTM) | |
|---|---|
| Revenue | NT$830.67m |
| Cost of Revenue | NT$1.17m |
| Gross Profit | NT$829.50m |
| Other Expenses | NT$356.76m |
| Earnings | NT$472.74m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.99 |
| Gross Margin | 99.86% |
| Net Profit Margin | 56.91% |
| Debt/Equity Ratio | 0% |
How did 6620 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/30 00:38 |
| End of Day Share Price | 2025/07/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Handa Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |